This goal was completed using a comparison of CMC numbers, including their pre- and post-treatment status, evaluation of PMEL and Melan-A marker expression, and assessment of serum levels of S100B and TIMP-1 proteins in representative blood samples from melanoma patients and healthy controls. This evidence concerns the gene S100B and melanoma.